This document outlines the use of saliva as a diagnostic sample for detecting SARS-CoV-2 infection, considering the advantages, limitations and uncertainties associated with the use of saliva as sample material.
This document aims to provide interim guidance on the risks for fully vaccinated individuals to develop or transmit
infection that will give rise to severe COVID-19 disease in the context of the current epidemiological and vaccine
coverage situation in the EU/EEA.
The aim of this document is to present the findings of a survey of EU/EEA countries carried out to ascertain
surveillance practices implemented to document and report suspected reinfection cases.
This document presents a coherent, yet non-prescriptive framework for tuning COVID-19 response measures in the European Union and European Economic Area (EU/EEA). Its aim is to ensure efficiency and encourage public trust and compliance, while continuing to protect the health of European citizens.
This document outlines the public health considerations for the use of self-tests to detect SARS-CoV-2 by public health authorities in the European Union/European Economic Area (EU/EEA). Only rapid antigen detection tests (RADTs) for self-testing for direct detection of SARS-CoV-2 virus particles in infectious individuals are considered within this document.
This document provides guidance based on scientific evidence regarding quarantine and testing of travellers in EU/EEA countries in the context of the emergence of SARS-CoV-2 variants of concern (VOCs).
This document aims to provide guidance to EU/EEA healthcare facilities and healthcare providers on infection prevention and control (IPC) measures for the management of suspected and confirmed cases of COVID-19 infection in healthcare settings, including long-term care facilities. It also offers guidance on the management of specimens at laboratories in the EU/EEA.
This technical guidance aims to provide guidelines to laboratories and relevant stakeholders in the European Union (EU), European Economic Area (EEA) and other countries in the WHO European region in making decisions on establishing sequencing capacities and capabilities, in making decisions on which technologies to use and/or in deciding on the role of sequencing for SARS-CoV-2 diagnostics, research, outbreak investigations and surveillance.